Impact of benzodiazepines on functional outcome and occurrence of pneumonia in stroke: Evidence from VISTA

VISTA collaborators

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Benzodiazepines have been proposed both as a neuroprotectant and risk factor for pneumonia in acute stroke. Aims: We assessed the impact of benzodiazepine exposure on the modified Rankin scale score distribution at 90 days as well as pneumonia rates among patients registered in a trials archive. Method: We used an age, baseline National Institutes of Health Stroke Score, and thrombolysis-rate adjusted Cochran-Mantel-Haenszel test to test significance (P) followed by proportional odds logistic regression analysis to estimate the odds ratios for improved modified Rankin scale score, and binary logistic regression to estimate the odds ratio for developing pneumonia. Results: Data were available for 5938 patients, of whom 1800 received benzodiazepines. No association of benzodiazepine use and overall stroke outcome could be found (odds ratio 0·90, 95% confidence interval 0·82-1·00, P=0·121). Pneumonia occurred in 12·8% of patients treated with benzodiazepines and in 13·6% of the controls (odds ratio 0·99, 95% confidence interval 0·83-1·18, P=0·904). Conclusion: In this nonrandomized comparison, treatment with benzodiazepines as a concomitant medication had no independent impact on stroke outcome.

Original languageEnglish (US)
Pages (from-to)890-894
Number of pages5
JournalInternational Journal of Stroke
Volume9
Issue number7
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Benzodiazepines
Pneumonia
Stroke
Odds Ratio
Logistic Models
Confidence Intervals
National Institutes of Health (U.S.)
Neuroprotective Agents
Regression Analysis

Keywords

  • Benzodiazepine
  • Mortality
  • Outcome
  • Pneumonia
  • Stroke

ASJC Scopus subject areas

  • Neurology
  • Medicine(all)

Cite this

Impact of benzodiazepines on functional outcome and occurrence of pneumonia in stroke : Evidence from VISTA. / VISTA collaborators.

In: International Journal of Stroke, Vol. 9, No. 7, 01.10.2014, p. 890-894.

Research output: Contribution to journalArticle

@article{313e879af9c94557a7adda74db9fd5c8,
title = "Impact of benzodiazepines on functional outcome and occurrence of pneumonia in stroke: Evidence from VISTA",
abstract = "Background: Benzodiazepines have been proposed both as a neuroprotectant and risk factor for pneumonia in acute stroke. Aims: We assessed the impact of benzodiazepine exposure on the modified Rankin scale score distribution at 90 days as well as pneumonia rates among patients registered in a trials archive. Method: We used an age, baseline National Institutes of Health Stroke Score, and thrombolysis-rate adjusted Cochran-Mantel-Haenszel test to test significance (P) followed by proportional odds logistic regression analysis to estimate the odds ratios for improved modified Rankin scale score, and binary logistic regression to estimate the odds ratio for developing pneumonia. Results: Data were available for 5938 patients, of whom 1800 received benzodiazepines. No association of benzodiazepine use and overall stroke outcome could be found (odds ratio 0·90, 95{\%} confidence interval 0·82-1·00, P=0·121). Pneumonia occurred in 12·8{\%} of patients treated with benzodiazepines and in 13·6{\%} of the controls (odds ratio 0·99, 95{\%} confidence interval 0·83-1·18, P=0·904). Conclusion: In this nonrandomized comparison, treatment with benzodiazepines as a concomitant medication had no independent impact on stroke outcome.",
keywords = "Benzodiazepine, Mortality, Outcome, Pneumonia, Stroke",
author = "{VISTA collaborators} and Benedikt Frank and Fulton, {Rachael L.} and Lees, {Kennedy R.} and Sanders, {Robert D.} and A. Alexandrov and Bath, {P. W.} and E. Bluhmki and N. Bornstein and L. Claesson and J. Curram and Davis, {S. M.} and G. Donnan and Diener, {H. C.} and M. Fisher and B. Gregson and J. Grotta and W. Hacke and Hennerici, {M. G.} and M. Hommel and M. Kaste and P. Lyden and J. Marler and K. Muir and Sacco, {Ralph L} and A. Shuaib and P. Teal and Wahlgren, {N. G.} and S. Warach and C. Weimar",
year = "2014",
month = "10",
day = "1",
doi = "10.1111/ijs.12148",
language = "English (US)",
volume = "9",
pages = "890--894",
journal = "International Journal of Stroke",
issn = "1747-4930",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Impact of benzodiazepines on functional outcome and occurrence of pneumonia in stroke

T2 - Evidence from VISTA

AU - VISTA collaborators

AU - Frank, Benedikt

AU - Fulton, Rachael L.

AU - Lees, Kennedy R.

AU - Sanders, Robert D.

AU - Alexandrov, A.

AU - Bath, P. W.

AU - Bluhmki, E.

AU - Bornstein, N.

AU - Claesson, L.

AU - Curram, J.

AU - Davis, S. M.

AU - Donnan, G.

AU - Diener, H. C.

AU - Fisher, M.

AU - Gregson, B.

AU - Grotta, J.

AU - Hacke, W.

AU - Hennerici, M. G.

AU - Hommel, M.

AU - Kaste, M.

AU - Lyden, P.

AU - Marler, J.

AU - Muir, K.

AU - Sacco, Ralph L

AU - Shuaib, A.

AU - Teal, P.

AU - Wahlgren, N. G.

AU - Warach, S.

AU - Weimar, C.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background: Benzodiazepines have been proposed both as a neuroprotectant and risk factor for pneumonia in acute stroke. Aims: We assessed the impact of benzodiazepine exposure on the modified Rankin scale score distribution at 90 days as well as pneumonia rates among patients registered in a trials archive. Method: We used an age, baseline National Institutes of Health Stroke Score, and thrombolysis-rate adjusted Cochran-Mantel-Haenszel test to test significance (P) followed by proportional odds logistic regression analysis to estimate the odds ratios for improved modified Rankin scale score, and binary logistic regression to estimate the odds ratio for developing pneumonia. Results: Data were available for 5938 patients, of whom 1800 received benzodiazepines. No association of benzodiazepine use and overall stroke outcome could be found (odds ratio 0·90, 95% confidence interval 0·82-1·00, P=0·121). Pneumonia occurred in 12·8% of patients treated with benzodiazepines and in 13·6% of the controls (odds ratio 0·99, 95% confidence interval 0·83-1·18, P=0·904). Conclusion: In this nonrandomized comparison, treatment with benzodiazepines as a concomitant medication had no independent impact on stroke outcome.

AB - Background: Benzodiazepines have been proposed both as a neuroprotectant and risk factor for pneumonia in acute stroke. Aims: We assessed the impact of benzodiazepine exposure on the modified Rankin scale score distribution at 90 days as well as pneumonia rates among patients registered in a trials archive. Method: We used an age, baseline National Institutes of Health Stroke Score, and thrombolysis-rate adjusted Cochran-Mantel-Haenszel test to test significance (P) followed by proportional odds logistic regression analysis to estimate the odds ratios for improved modified Rankin scale score, and binary logistic regression to estimate the odds ratio for developing pneumonia. Results: Data were available for 5938 patients, of whom 1800 received benzodiazepines. No association of benzodiazepine use and overall stroke outcome could be found (odds ratio 0·90, 95% confidence interval 0·82-1·00, P=0·121). Pneumonia occurred in 12·8% of patients treated with benzodiazepines and in 13·6% of the controls (odds ratio 0·99, 95% confidence interval 0·83-1·18, P=0·904). Conclusion: In this nonrandomized comparison, treatment with benzodiazepines as a concomitant medication had no independent impact on stroke outcome.

KW - Benzodiazepine

KW - Mortality

KW - Outcome

KW - Pneumonia

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84907896324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907896324&partnerID=8YFLogxK

U2 - 10.1111/ijs.12148

DO - 10.1111/ijs.12148

M3 - Article

C2 - 24148353

AN - SCOPUS:84907896324

VL - 9

SP - 890

EP - 894

JO - International Journal of Stroke

JF - International Journal of Stroke

SN - 1747-4930

IS - 7

ER -